Table 2.

Patients’ clinical and pathological characteristics by dichotomized ER and PR expression

	All cases (n=416)	ER, No. (%)			PR, No. (%)
		Positive (n=261)	Negative (n=155)	P-value	Positive (n=257)	Negative (n=159)	P-value
Age				0.0922			0.0926
<36 years	26 (6%)	15 (6%)	15 (10%)		14 (6%)	16 (10%)
36–50 years	204 (49%)	135 (52%)	65 (42%)		132 (51%)	68 (43%)
>50 years	186 (45%)	111 (43%)	75 (48%)		111 (43%)	75 (47%)
Tumor size				0.0057			0.1190
≤2 cm	167 (40%)	120 (46%)	47 (30%)		111 (43%)	56 (35%)
3–5 cm	216 (52%)	124 (48%)	92 (59%)		130 (51%)	86 (54%)
>5 cm	33 (8%)	17 (7%)	16 (10%)		16 (6%)	17 (11%)
Axillary lymph node				0.9399			0.0271
None	232 (56%)	148 (57%)	84 (54%)		158 (61%)	74 (47%)
1–3	96 (23%)	59 (23%)	37 (24%)		53 (21%)	43 (27%)
4–9	54 (13%)	34 (13%)	20 (13%)		29 (11%)	25 (16%)
≥10	34 (8%)	20 (8%)	14 (9%)		17 (7%)	17 (11%)
AJCC stage				0.0445			0.0198
I	114 (27%)	82 (31%)	32 (21%)		82 (32%)	32 (20%)
II	209 (50%)	121 (46%)	88 (57%)		125 (49%)	84 (53%)
III	93 (22%)	58 (22%)	35 (23%)		50 (19%)	43 (27%)
Histologic subtype				0.0006			0.3523
Ductal	391 (94%)	237 (91%)	154 (99%)		238 (93%)	153 (96%)
Lobular	8 (2%)	8 (3%)	0 (0%)		5 (2%)	3 (2%)
Mucinous	13 (3%)	13 (5%)	0 (0%)		11 (4%)	2 (1%)
Others	4 (1%)	3 (1%)	1 (1%)		3 (1%)	1 (1%)
Histologic grade				<0.0001			<0.0001
I	103 (25%)	78 (30%)	25 (16%)		79 (31%)	24 (15%)
II	164 (39%)	115 (44%)	49 (32%)		113 (44%)	51 (32%)
III	98 (24%)	33 (13%)	65 (42%)		37 (14%)	61 (38%)
Not available	51 (12%)	35 (13%)	16 (10%)		28 (11%)	23 (15%)
Neoadjuvant or adjuvant chemotherapy				0.3577			0.3098
Yes	262 (63%)	160 (61%)	102 (66%)		157 (61%)	105 (66%)
No	154 (37%)	101 (39%)	53 (34%)		100 (39%)	54 (34%)